-
04:59:50 AM

KRYS Stock News

05/19/23 1:57 PM
Nasdaq : KRYS
fda approvallow float
Krystal Biotech Receives FDA Approval for the First-Ever Redosable Gene Therapy, VYJUVEK™ (beremagene geperpavec-svdt) for the Treatment of Dystrophic Epidermolysis Bullosa
Dystrophic Epidermolysis Bullosa (DEB) is a serious rare genetic disease that affects the skin and mucosal tissues and is caused by one or more mutations in the COL7A1 gene, resulting in lack of production of functional type VII collagen (COL7) protein VYJUVEK is a topical gel that addresses the
RHEA-AI
neutral
04/24/23 7:00 AM
Nasdaq : KRYS
clinical triallow float
Krystal Biotech Announces Clinical Data on Topical Application of B-VEC to the Eye to Treat Ocular Complications in a Patient with Dystrophic Epidermolysis Bullosa Under a Compassionate Use Program
Data presented at Association for Research in Vision and Ophthalmology Annual Meeting on April 23, 2023 Topical application of B-VEC to the eye was well tolerated and patient showed significant improvement of visual acuity and complete corneal re-epithelization PITTSBURGH, April 24, 2023 (GLOBE
RHEA-AI
neutral